Approval · Notice of Compliance 31301 · 2023
ALHEMO: Notice of Compliance 31301
Issued July 26, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 31301
- Date
- July 26, 2023
- Company
- Novo Nordisk Canada IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- Other
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ALHEMO | Not yet assigned | — |
Medicinal ingredients
- CONCIZUMAB 15 MG per 1.5ML
- CONCIZUMAB 60 MG per 1.5ML
- CONCIZUMAB 150 MG per 1.5ML
- CONCIZUMAB 300 MG per 3ML